<DOC>
	<DOC>NCT01725594</DOC>
	<brief_summary>This is a two-part Phase 1 placebo-controlled, double-blind, randomized single and multiple ascending dose study. In Part A, CAT-2003 is administered as a single dose; at two doses (1000 and 2000 mg), subjects will return for a second dose of CAT-2003 or placebo after a high fat meal. In Part B, CAT-2003 is administered for 14 consecutive days.</brief_summary>
	<brief_title>A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Major Provision of written informed consent prior to any studyspecific procedure; Good health as determined by medical history, physical examination, vital signs, ECG, and clinical laboratory measurements; Satisfies one of the following: 1. Females not of childbearing potential: nonpregnant and nonlactating; surgically sterile or postmenopausal for 2 years or at least 1 year with a follicle stimulating hormone assessment (FSH) greater than or equal to 40 IU/L; OR 2. Males: surgically sterile, abstinent, or subject or partner is utilizing an acceptable contraceptive method during and 3 months after the last study dose; Major Clinically significant disease that requires a physician's care and/or would interfere with study evaluations Clinically significant electrocardiogram (ECG) abnormalities or laboratory results as assessed by the investigator, such as QTcF &gt;450; Use of any investigational drug or participation in any investigational study within 30 days prior to screening or 5 halflives of the study agent, whichever is longer;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>